HIF2A Germline-Mutation-Induced Polycythemia in a Patient with VHL-Associated Renal-Cell Carcinoma
Document Type
Article
Publication Date
12-2-2017
Abstract
In this study, we report here a rare case of polycythemia and cRCC in the same patient, which may be helpful in understanding clinical features and molecular mechanisms underlying VHL-mutation-associated cRCC and polycythemia induced by germline mutation of HIF2A. Firstly, we identified a rare but well studied germline mutation resulting in polycythemia in HIF2A (c.1609G>A, p.Gly537Trp) in the blood of the patient and his daughter. Meanwhile, we identified an inactivating VHL mutation (c.391A>T, p.N131Y), as well as TP53 mutation(c.977A>T, p.E326V) and mTOR mutation(c.7498A>T, p.I2500F) in renal cancer tissue. Moreover, protein levels of VHL, HIF1A, HIF2A, EPO, and VEGF estimated by immunohistochemical staining substantiated hyperactivation of the oxygen-sensing pathway. In addition, we identified 158 somatic SNP/indel mutations, including 90 missense/nonsense/splice/stop-loss mutations by whole-exome sequencing (WES) of the tumor specimen and matched normal DNA.
Publication Title
Cancer Biology & Therapy
Volume
18
Issue
12
First Page
944
Last Page
947
PubMed ID
29172931
Recommended Citation
Liu, Qiuli; Tong, Dali; Liu, Gaolei; Yi, Yuting; Zhang, Dianzheng; Zhang, Jun; Zhang, Yao; Huang, Zaoming; Li, Yaoming; Chen, Rongrong; Guan, Yanfang; Yi, Xin; and Jiang, Jun, "HIF2A Germline-Mutation-Induced Polycythemia in a Patient with VHL-Associated Renal-Cell Carcinoma" (2017). PCOM Scholarly Papers. 1894.
https://digitalcommons.pcom.edu/scholarly_papers/1894
Comments
This article was published in Cancer Biology & Therapy, Volume 18, Issue 12, Pages 944-947.
The published version is available at http://dx.doi.org/10.1080/15384047.2017.1394553.
Copyright © 2017.